Lintitript

CAS No. 136381-85-6

Lintitript( SR 27897 )

Catalog No. M26740 CAS No. 136381-85-6

Lintitript is a selective antagonist of CCK1 with EC50s of 6 nM and 200 nM for CCK1 and CCK2. The Ki value is 0.2 nM for CCK1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 120 In Stock
2MG 65 In Stock
5MG 107 In Stock
10MG 163 In Stock
25MG 363 In Stock
50MG 667 In Stock
100MG 893 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lintitript
  • Note
    Research use only, not for human use.
  • Brief Description
    Lintitript is a selective antagonist of CCK1 with EC50s of 6 nM and 200 nM for CCK1 and CCK2. The Ki value is 0.2 nM for CCK1.
  • Description
    Lintitript is a selective antagonist of CCK1 with EC50s of 6 nM and 200 nM for CCK1 and CCK2. The Ki value is 0.2 nM for CCK1.(In Vitro):Lintitript inhibited the CCK 2 site in guinea pig cortex with an IC2 of 479 nM. lintitript (0.5 nM) increased the dissociation constant of CCK on CCKA receptors with Kds between 1.8 and 7.2 nM without altering the maximum number of receptors. lintitript antagonized CCK-stimulated isolated rat pancreatic follicles in (amylase release and CCK-induced gallbladder contraction in guinea pigs with pA2s of 7.50 and 9.57). lintitript inhibited the binding of [125I]CCK to the rat pancreatic CCK1 receptor site with IC50 of 0.58 nM in a concentration-dependent manner.(In Vivo):Lintitript (1 mg/kg, i.v.) completely reversed CCK-induced amylase secretion. lintitript inhibited CCK-induced gastric and gallbladder emptying in mice with ED50s of 3 μg/kg and 72 μg/kg. lintitript (p.o.) was active in the gallbladder emptying protocol of egg yolk-induced endogenous CCK release, with an ED50 of 27 μg/kg .
  • In Vitro
    In vitro, Lintitript (SR 27897) is a competitive antagonist of cholecystokinin (CCK)-stimulated amylase release in isolated rat pancreatic acini (pA2 = 7.50) and of CCK-induced guinea pig gall bladder contractions (pA2 = 9.57). Lintitript produces concentration dependent inhibition of [125I]CCK binding to CCK1 receptor sites in the rat pancreas (IC50 value of 0.58 nM) and also to CCK 2 sites in the guinea pig cortex (IC2 value of 479 nM). Lintitript inhibits [125I]gastrin binding to gastrin receptors. Lintitript (0.5 nM) increases the dissociation constant of CCK for the CCK A receptor (Kd = 1.8 to 7.2 nM) without modifying the maximum number of receptors (Bmax = 1800 to 1770 fmol/mg).
  • In Vivo
    Lintitript (SR 27897; 1 mg/kg, i.v.) completely reverses the CCK-induced amylase secretion. Lintitript also inhibits CCK-induced gastric and gallbladder emptying in mice (ED50s = 3 and 72 μg/kg, respectively). Lintitript is also very active (ED50 = 27 μg/kg p.o.) in the gall bladder emptying protocol with egg yolk as an inducer of endogenous CCK release.
  • Synonyms
    SR 27897
  • Pathway
    GPCR/G Protein
  • Target
    Cholecystokinin Receptor
  • Recptor
    Fungal
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    136381-85-6
  • Formula Weight
    411.86
  • Molecular Formula
    C20H14ClN3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (242.80 mM)
  • SMILES
    OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Vetter ND, et al. A previously unrecognized kanosamine biosynthesis pathway in Bacillus subtilis. J Am Chem Soc. 2013 Apr 24;135(16):5970-3.
molnova catalog
related products
  • SR146131

    SR146131 (SR-146131) a small molecule positive allosteric modulator of the type 1 cholecystokinin receptor (CCK1R) with pEC50 of 10.34.

  • Lorglumide sodium sa...

    Lorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist.

  • PF-04756956

    A potent, selective CCK1 receptor agonist with EC50 of 0.47 nM; elicits no biological response at the CCK2 receptors.